<div id="readability-page-1"><p>JPMorgan Chase &amp; Co. lowered its holdings in shares of  Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 71.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor  owned 153,571 shares of the company's stock after selling 385,349 shares during the quarter. JPMorgan Chase &amp; Co. owned approximately 0.32% of Amphastar Pharmaceuticals worth $5,702,000 at the end of the most recent reporting period.</p><ul><li>Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts</li></ul><p>Several other institutional investors and hedge funds also recently added to or reduced their stakes in AMPH. Pacer Advisors Inc. lifted its stake in  Amphastar Pharmaceuticals by 51,977.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after purchasing an additional 1,347,775 shares in the last quarter.  Boston Trust Walden Corp grew its stake in shares of  Amphastar Pharmaceuticals by 81.4% during the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock valued at $36,347,000 after buying an additional 439,281 shares during the last quarter.  Boston Partners bought a new stake in shares of  Amphastar Pharmaceuticals during the fourth quarter valued at approximately $15,778,000.  Wealthfront Advisers LLC purchased a new position in  Amphastar Pharmaceuticals during the 4th quarter worth $9,268,000.  Finally, Raymond James Financial Inc. bought a new stake in  Amphastar Pharmaceuticals during the 4th quarter valued at $3,450,000. Institutional investors own  65.09% of the company's stock. </p><h2>Insider Buying and Selling at Amphastar Pharmaceuticals</h2><p>In related news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the transaction, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 27.10% of the stock is owned by insiders. </p><h2>Analysts Set New Price Targets</h2><ul><li>Promising Small Biotech Amphastar Sees Actionable Pullback </li></ul><p>Several research analysts recently weighed in on AMPH shares. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a &#34;neutral&#34; rating on the stock in a research report on Friday, March 21st. Needham &amp; Company LLC  restated a &#34;hold&#34; rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th.</p><p><b>Read Our Latest Stock Analysis on AMPH</b></p><h2>Amphastar Pharmaceuticals Stock Up 1.6 %</h2><p>Shares of AMPH opened at $23.35 on Friday. The stock's 50-day moving average price is $27.78 and its 200-day moving average price is $37.36. Amphastar Pharmaceuticals, Inc. has a 52 week low of $22.64 and a 52 week high of $53.96. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of 7.78, a PEG ratio of 2.19 and a beta of 0.79. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. </p><h2>Amphastar Pharmaceuticals Company Profile</h2> (Free Report)<p>Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Amphastar Pharmaceuticals</li><li>What Are Dividends? Buy the Best Dividend Stocks</li><li>3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks</li><li>What is the Dogs of the Dow Strategy? Overview and Examples</li><li>These 3 Stocks Have Huge Last 12 Months Shareholder Yields</li><li>Growth Stocks: What They Are, Examples and How to Invest</li><li>Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?</li></ul><p><strong>Want to see what other hedge funds are holding AMPH?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Amphastar Pharmaceuticals Right Now?</h2><p>Before you consider Amphastar Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.</p><p>While Amphastar Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AMPH

<p>JPMorgan Chase & Co. has reduced its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) by 71.5%, selling 385,349 shares in the 4th quarter, leaving it with 153,571 shares valued at approximately $5.7 million. Other institutional investors have also adjusted their stakes, with Pacer Advisors Inc. significantly increasing its holdings. The stock opened at $23.35, with a 52-week range of $22.64 to $53.96. Analysts have set new price targets, with Piper Sandler lowering its target from $36.00 to $32.00, maintaining a "neutral" rating.</p>

JPMorgan Chase & Co. Sells 385,349 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)